April 29th 2024
Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Pembrolizumab Granted 4 Approvals in Japan for High-Risk TNBC, RCC, and More
October 2nd 2022Japan’s Ministry of Health, Labor and Welfare approved pembrolizumab for use in 4 indications, including high-risk, early-stage triple-negative breast cancer, stage IIB or IIC melanoma, adjuvant renal cell carcinoma, and recurrent/metastatic cervical cancer.
Durvalumab Plus CRT Fails to Meet PFS End Point in High-Risk Locally Advanced Cervical Cancer
September 30th 2022Results from the phase 3 CALLA trial indicated that durvalumab in combination with chemoradiotherapy did not yield a meaningful improvement in progression-free survival compared with chemoradiotherapy alone in high-risk locally advanced cervical cancer.
Jyoti S. Mayadev, MD, on Atezolizumab for Locally Advanced, Node-Positive Cervical Cancer
April 7th 2022At SGO 2022, Jyoti S. Mayadev, MD presented results of the NRG-GY017 trial of atezolizumab as either an immune primer or with chemoradiation for certain patients with locally advanced cervical cancer.
Jyoti Mayadev, MD, Provides Perspective on Atezolizumab in Locally Advanced Cervical Cancer
March 28th 2022At SGO 2022, CancerNetwork® spoke with Jyoti Mayadev, MD, about a clinical trial involving immune priming with the PD-L1 inhibitor atezolizumab for patients with locally advanced cervical cancer.
Lifileucel Plus Pembrolizumab Yields Positive ORR in Advanced Cancers
November 16th 2021Patients with melanoma, head and neck squamous cell carcinoma, and cervical cancer who had not previously received immunotherapy and were treated with lifileucel plus pembrolizumab experienced promising overall response rates compared favorably with historical data on pembrolizumab monotherapy.
Treatment of Locally Advanced Cervical Cancer With Kidney Failure and Comorbidities
In this edition of Clinical Quandaries Eder A. Arango Bravo, MD, and colleagues present a 63 year old woman who has cervical cancer with kidney failure and additional comorbidities.
Cemiplimab Receives Priority Review From the FDA In Recurrent or Metastatic Cervical Cancer
October 4th 2021Patients with recurrent or metastatic cervical cancer treated with cemiplimab experienced an improved overall survival, progression-free survival, and overall response rate, leading to priority review from the FDA.